BceAB-type antibiotic resistance transporters appear to act by target protection of cell wall synthesis

Carolin M. Kobras, Hannah Piepenbreier, Jennifer Emenegger, Andre Sim, Georg Fritz, Susanne Gebhard

Research output: Contribution to journalArticle

117 Downloads (Pure)

Abstract

Resistance against cell wall-active antimicrobial peptides in bacteria is often mediated by transporters. In low GC-content Gram-positive bacteria, a common type of such transporters are BceAB-like systems, which frequently provide high-level resistance against peptide antibiotics that target intermediates of the lipid II cycle of cell wall synthesis. How a transporter can offer protection from drugs that are active on the cell surface, however, has presented researchers with a conundrum. Multiple theories have been discussed, ranging from removal of the peptides from the membrane, internalisation of the drug for degradation, to removal of the cellular target rather than the drug itself. To resolve this much-debated question, we here investigated the mode-of-action of the transporter BceAB of Bacillus subtilis. We show that it does not inactivate or import its substrate antibiotic bacitracin. Moreover, we present evidence that the critical factor driving transport activity is not the drug itself, but instead the concentration of drug-target complexes in the cell. Our results, together with previously reported findings, lead us to propose that BceAB-type transporters act by transiently freeing lipid II cycle intermediates from the inhibitory grip of antimicrobial peptides, and thus provide resistance through target protection of cell wall synthesis. Target protection has so far only been reported for resistance against antibiotics with intracellular targets, such as the ribosome. However, this mechanism offers a plausible explanation for the use of transporters as resistance determinants against cell wall-active antibiotics in Gram-positive bacteria where cell wall synthesis lacks the additional protection of an outer membrane.
Original languageEnglish
JournalbioRxiv
DOIs
Publication statusPublished - 11 Nov 2019

Fingerprint

Microbial Drug Resistance
Cell Wall
Peptides
Pharmaceutical Preparations
Gram-Positive Bacteria
Anti-Bacterial Agents
Bacitracin
Membranes
Base Composition
Hand Strength
Bacillus subtilis
Ribosomes
Research Personnel
Bacteria
muramyl-NAc-(pentapeptide)pyrophosphoryl-undecaprenol

Cite this

Kobras, Carolin M. ; Piepenbreier, Hannah ; Emenegger, Jennifer ; Sim, Andre ; Fritz, Georg ; Gebhard, Susanne. / BceAB-type antibiotic resistance transporters appear to act by target protection of cell wall synthesis. In: bioRxiv. 2019.
@article{c0ca3ba65bdf4a5ba40d89f71ef2b7d1,
title = "BceAB-type antibiotic resistance transporters appear to act by target protection of cell wall synthesis",
abstract = "Resistance against cell wall-active antimicrobial peptides in bacteria is often mediated by transporters. In low GC-content Gram-positive bacteria, a common type of such transporters are BceAB-like systems, which frequently provide high-level resistance against peptide antibiotics that target intermediates of the lipid II cycle of cell wall synthesis. How a transporter can offer protection from drugs that are active on the cell surface, however, has presented researchers with a conundrum. Multiple theories have been discussed, ranging from removal of the peptides from the membrane, internalisation of the drug for degradation, to removal of the cellular target rather than the drug itself. To resolve this much-debated question, we here investigated the mode-of-action of the transporter BceAB of Bacillus subtilis. We show that it does not inactivate or import its substrate antibiotic bacitracin. Moreover, we present evidence that the critical factor driving transport activity is not the drug itself, but instead the concentration of drug-target complexes in the cell. Our results, together with previously reported findings, lead us to propose that BceAB-type transporters act by transiently freeing lipid II cycle intermediates from the inhibitory grip of antimicrobial peptides, and thus provide resistance through target protection of cell wall synthesis. Target protection has so far only been reported for resistance against antibiotics with intracellular targets, such as the ribosome. However, this mechanism offers a plausible explanation for the use of transporters as resistance determinants against cell wall-active antibiotics in Gram-positive bacteria where cell wall synthesis lacks the additional protection of an outer membrane.",
author = "Kobras, {Carolin M.} and Hannah Piepenbreier and Jennifer Emenegger and Andre Sim and Georg Fritz and Susanne Gebhard",
year = "2019",
month = "11",
day = "11",
doi = "10.1101/835702",
language = "English",
journal = "bioRxiv",
publisher = "Cold Spring Harbor Laboratory",

}

BceAB-type antibiotic resistance transporters appear to act by target protection of cell wall synthesis. / Kobras, Carolin M.; Piepenbreier, Hannah; Emenegger, Jennifer; Sim, Andre; Fritz, Georg; Gebhard, Susanne.

In: bioRxiv, 11.11.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - BceAB-type antibiotic resistance transporters appear to act by target protection of cell wall synthesis

AU - Kobras, Carolin M.

AU - Piepenbreier, Hannah

AU - Emenegger, Jennifer

AU - Sim, Andre

AU - Fritz, Georg

AU - Gebhard, Susanne

PY - 2019/11/11

Y1 - 2019/11/11

N2 - Resistance against cell wall-active antimicrobial peptides in bacteria is often mediated by transporters. In low GC-content Gram-positive bacteria, a common type of such transporters are BceAB-like systems, which frequently provide high-level resistance against peptide antibiotics that target intermediates of the lipid II cycle of cell wall synthesis. How a transporter can offer protection from drugs that are active on the cell surface, however, has presented researchers with a conundrum. Multiple theories have been discussed, ranging from removal of the peptides from the membrane, internalisation of the drug for degradation, to removal of the cellular target rather than the drug itself. To resolve this much-debated question, we here investigated the mode-of-action of the transporter BceAB of Bacillus subtilis. We show that it does not inactivate or import its substrate antibiotic bacitracin. Moreover, we present evidence that the critical factor driving transport activity is not the drug itself, but instead the concentration of drug-target complexes in the cell. Our results, together with previously reported findings, lead us to propose that BceAB-type transporters act by transiently freeing lipid II cycle intermediates from the inhibitory grip of antimicrobial peptides, and thus provide resistance through target protection of cell wall synthesis. Target protection has so far only been reported for resistance against antibiotics with intracellular targets, such as the ribosome. However, this mechanism offers a plausible explanation for the use of transporters as resistance determinants against cell wall-active antibiotics in Gram-positive bacteria where cell wall synthesis lacks the additional protection of an outer membrane.

AB - Resistance against cell wall-active antimicrobial peptides in bacteria is often mediated by transporters. In low GC-content Gram-positive bacteria, a common type of such transporters are BceAB-like systems, which frequently provide high-level resistance against peptide antibiotics that target intermediates of the lipid II cycle of cell wall synthesis. How a transporter can offer protection from drugs that are active on the cell surface, however, has presented researchers with a conundrum. Multiple theories have been discussed, ranging from removal of the peptides from the membrane, internalisation of the drug for degradation, to removal of the cellular target rather than the drug itself. To resolve this much-debated question, we here investigated the mode-of-action of the transporter BceAB of Bacillus subtilis. We show that it does not inactivate or import its substrate antibiotic bacitracin. Moreover, we present evidence that the critical factor driving transport activity is not the drug itself, but instead the concentration of drug-target complexes in the cell. Our results, together with previously reported findings, lead us to propose that BceAB-type transporters act by transiently freeing lipid II cycle intermediates from the inhibitory grip of antimicrobial peptides, and thus provide resistance through target protection of cell wall synthesis. Target protection has so far only been reported for resistance against antibiotics with intracellular targets, such as the ribosome. However, this mechanism offers a plausible explanation for the use of transporters as resistance determinants against cell wall-active antibiotics in Gram-positive bacteria where cell wall synthesis lacks the additional protection of an outer membrane.

U2 - 10.1101/835702

DO - 10.1101/835702

M3 - Article

JO - bioRxiv

JF - bioRxiv

ER -